Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression

BACKGROUND: Sorafenib is a first-line treatment option for advanced hepatocellular carcinoma (HCC) patients; however, survival predictors upon progression have not been well characterized. In the present study, we aimed to show the efficacy of multidisciplinary therapy for patients who had failed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Masaaki, Numata, Kazushi, Hara, Koji, Nozaki, Akito, Fukuda, Hiroyuki, Chuma, Makoto, Maeda, Shin, Tanaka, Katsuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498900/
https://www.ncbi.nlm.nih.gov/pubmed/28717362
http://dx.doi.org/10.1155/2017/5728946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498900/
https://www.ncbi.nlm.nih.gov/pubmed/28717362
http://dx.doi.org/10.1155/2017/5728946

Ejemplares similares